tiprankstipranks
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clovis Oncology (CLVS), Veru (VERU) and Albireo Pharma (ALBO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Clovis Oncology (CLVSResearch Report), Veru (VERUResearch Report) and Albireo Pharma (ALBOResearch Report).

Clovis Oncology (CLVS)

H.C. Wainwright analyst Edward White maintained a Hold rating on Clovis Oncology today. The company’s shares closed last Wednesday at $2.18.

According to TipRanks.com, White has 0 stars on 0-5 stars ranking scale with an average return of -25.5% and a 27.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

The the analyst consensus on Clovis Oncology is currently a Hold rating.

See Insiders’ Hot Stocks on TipRanks >>

Veru (VERU)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Veru today and set a price target of $24.00. The company’s shares closed last Wednesday at $13.02.

According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of -11.7% and a 32.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Veru with a $28.75 average price target, implying a 148.9% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $55.00 price target.

Albireo Pharma (ALBO)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Albireo Pharma today and set a price target of $80.00. The company’s shares closed last Wednesday at $22.75.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.3% and a 37.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Aurinia Pharmaceuticals, and Paratek Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Albireo Pharma with a $69.00 average price target, implying a 209.0% upside from current levels. In a report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $72.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CLVS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed